Kevin G Pinney

US Patent:

6350777, Feb 26, 2002

Filed:

Dec 15, 2000

Appl. No.:

09/738394

Inventors:

Kevin G. Pinney - Hewitt TX
George R. Pettit - Paradise Valley AZ
Vani P. Mocharla - Waco TX
Maria del Pilar Mejia - Evanston IL
Anupama Shirali - Pune, IN

Assignee:

Baylor University
Arizona Disease Control Research Commission

International Classification:

A61K 3134

US Classification:

514469, 514419, 514416, 514721, 549468, 549469, 548492, 548493, 568644, 568510

Abstract:

Methoxy and ethoxy substituted 3-aroyl-2-arylbenzo[b]thiophenes and benzo[b]thiophene analogues are described for use in inhibiting tubulin polymerization. The compounds use for treating tumor cells is also described. Additional aspects described here are certain diaryl ether benzo[b]thiophene derivatives. Also described are particular analogs derived from dihydronaphthalene which have proven particularly effective. Certain new benzofuran analogs are described, as well as certain sulfur oxide benzo[b]thiophene analogs. Important compounds described herein include the first nitrogen-containing derivatives of combretastatin. These include nitro, amino and azide combrdtastatin derivatives.

US Patent:

6593374, Jul 15, 2003

Filed:

Mar 12, 2001

Appl. No.:

09/804280

Inventors:

Kevin G. Pinney - Hewitt TX
Vani P. Mocharla - Waco TX
Zhi Chen - Hamden CT
Charles M. Garner - McGregor TX
Anjan Ghatak - Waco TX
James M. Dorsey - Waco TX

Assignee:

Baylor University - Waco TX

International Classification:

A61K 31075

US Classification:

514721, 568633, 564443, 558197

Abstract:

A diverse set of tubulin binding ligands have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining arylâaryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates capable of demonstrating selective targeting and destruction of tumor cell vasculature.

US Patent:

6849656, Feb 1, 2005

Filed:

Sep 15, 2000

Appl. No.:

10/070484

Inventors:

Kevin Pinney - Woodway TX, US
Feng Wang - Jeffersonville PA, US
Mallinath Hadimani - Waco TX, US

Assignee:

Baylor University - Waco TX

International Classification:

A61K 31404
C07D20912

US Classification:

514419, 548491, 548492, 548469

Abstract:

Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as prodrugs, may well prove to be tumor selective vascular targeting and destruction chemotherapeutic agents or to have anti-angiogenesis activity resulting in the selective prevention and/or destruction of tumor cell vasculature.

US Patent:

6919324, Jul 19, 2005

Filed:

Oct 28, 2002

Appl. No.:

10/281528

Inventors:

David J. Chaplin - Watlington, GB
Robert Ronald Kane - Waco TX, US
Kevin G. Pinney - Woodway TX, US
Joseph Anthony Prezioso - Boston MA, US
Klaus Edvardsen - Klampenborg, DK

Assignee:

Oxigene, Inc. - Waltham MA
Baylor University - Waco TX

International Classification:

A61K031/661
C07F009/09

US Classification:

514114, 558166, 558169

Abstract:

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

US Patent:

6956054, Oct 18, 2005

Filed:

Aug 14, 2002

Appl. No.:

10/218833

Inventors:

Ronald W. Pero - Arlington VT, US
David Sherris - Jamaica Plain MA, US
Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - Waco TX, US
Zhi Chen - West Haven CT, US

Assignee:

Baylor University - Waco TX
OXiGENE, Inc. - Waltham MA

International Classification:

A61K031/40
A61K031/38

US Classification:

514419, 514415, 514443, 514733, 514731, 424600, 424601, 424602, 424603, 424604, 424605

Abstract:

Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

US Patent:

7001926, Feb 21, 2006

Filed:

Apr 1, 2003

Appl. No.:

10/404525

Inventors:

Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - San Diego CA, US
Zhi Chen - Hamden CT, US
Usha R. Ghatak, legal representative - West Bengal, IN
Mallinath Hadimani - Waco TX, US
Jimmy Kessler - Sugarland TX, US
James M. Dorsey - Durham NC, US
Klaus Edvardsen - Klampenborg, DK
David J. Chaplin - Oxford, GB
Joseph Prezioso - Boston MA, US

Assignee:

Oxigene, Inc. - Waltham MA
Baylor University - Waco TX

International Classification:

A61K 31/075
C07C 41/00

US Classification:

514721, 568633

Abstract:

A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

US Patent:

7091240, Aug 15, 2006

Filed:

Apr 29, 2003

Appl. No.:

10/425462

Inventors:

Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - Waco TX, US
Zhi Chen - Hamden CT, US
Charles M. Garner - Waco TX, US
Mallinath Hadimani - Waco TX, US
Raymond Kessler - Sugarland TX, US
James M. Dorsey - Durham NC, US
Klaus Edvardsen - Klampenborg, DK
David J. Chaplin - Watlington, CA
Joseph Prezioso - Boston MA, US
Usha Ghatak, legal representative - Salt Lake City UT, US

Assignee:

Oxigene, Inc. - Watertown MA
Baylor University - Waco TX

International Classification:

A61K 31/34
C07D 307/93

US Classification:

514469, 549468

Abstract:

A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

US Patent:

7384925, Jun 10, 2008

Filed:

Jul 18, 2005

Appl. No.:

11/183556

Inventors:

David J. Chaplin - Watlington, GB
Robert Ronald Kane - Waco TX, US
Kevin G. Pinney - Woodway TX, US
Joseph Anthony Prezioso - Boston MA, US
Klaus Edvardsen - Klampenborg, DK

Assignee:

OXiGENE, Inc. - Waltham MA
Baylor University - Waco TX

International Classification:

A61K 31/661
C07F 9/09

US Classification:

514114, 558 70, 558155, 558166, 558169

Abstract:

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.